



Please type a plus sign (+) inside this box →



02-09-07

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/509,773																																	
		Filing Date	April 14, 2005																																	
		First Named Inventor	DELANEY, ALLEN D.																																	
		Group Art Unit	1642																																	
		Examiner Name	Aeder, Sean E.																																	
Total Number of Pages in This Submission		Attorney Docket Number	KINE-040																																	
ENCLOSURES (check all that apply)																																				
<table border="1"><tr><td><input checked="" type="checkbox"/> Petition for Extension of Time</td><td><input type="checkbox"/> Assignment Papers (for an Application)</td><td><input type="checkbox"/> After Allowance Communication to Group</td></tr><tr><td><input checked="" type="checkbox"/> USPTO Credit Card Form 2038</td><td><input type="checkbox"/> Drawing(s)</td><td><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences</td></tr><tr><td><input type="checkbox"/> Amendment / Reply</td><td><input type="checkbox"/> Licensing-related Papers</td><td><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)</td></tr><tr><td><input type="checkbox"/> After Final</td><td><input type="checkbox"/> Petition</td><td><input type="checkbox"/> Proprietary Information</td></tr><tr><td><input type="checkbox"/> Affidavits/declaration(s)</td><td><input type="checkbox"/> Petition to Convert to a Provisional Application</td><td><input checked="" type="checkbox"/> Restriction Election</td></tr><tr><td><input type="checkbox"/> Extension of Time Request</td><td><input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address</td><td><input checked="" type="checkbox"/> Return postcard</td></tr><tr><td><input type="checkbox"/> Express Abandonment Request</td><td><input type="checkbox"/> Terminal Disclaimer</td><td></td></tr><tr><td><input type="checkbox"/> Information Disclosure Statement</td><td><input type="checkbox"/> Request for Refund</td><td></td></tr><tr><td><input type="checkbox"/> Certified Copy of Priority Documents</td><td><input type="checkbox"/> CD, Number of CD(s)</td><td></td></tr><tr><td><input type="checkbox"/> Response to Missing Parts/ Incomplete Application</td><td></td><td></td></tr><tr><td><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53</td><td></td><td></td></tr></table>				<input checked="" type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group	<input checked="" type="checkbox"/> USPTO Credit Card Form 2038	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information	<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input checked="" type="checkbox"/> Restriction Election	<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Return postcard	<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer		<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund		<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)		<input type="checkbox"/> Response to Missing Parts/ Incomplete Application			<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
<input checked="" type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group																																		
<input checked="" type="checkbox"/> USPTO Credit Card Form 2038	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences																																		
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)																																		
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information																																		
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input checked="" type="checkbox"/> Restriction Election																																		
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Return postcard																																		
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer																																			
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund																																			
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)																																			
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application																																				
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53																																				
Remarks																																				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT																																				
Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36,677 BOZCEVIC, FIELD & FRANCIS, LLP																																			
Signature																																				
Date	February 7, 2007																																			
EXPRESS MAIL LABEL NO. EV 687 639 189 US																																				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 687 639 189 US

RESTRICTION ELECTION Address to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Docket No.	KINE-040
	Application No.	10/509,773
	Confirmation No.	3141
	Filing Date	April 14, 2005
	Examiner	Aeder, Sean E.
	Group Art Unit	1642

Sir:

This communication is submitted in response to the Restriction Requirement dated August 8, 2006 for which a one-month period for response was given. A Petition for a five-month extension of time is filed herewith. Accordingly, this Restriction Election is timely filed.

The Examiner therein required election of one of the following groups of claims:

Group 1: Claim 1, as specifically drawn to a method of screening for biologically active agents comprising combining a candidate biologically active agent with a specific polypeptide and determining the effect of said agent on phosphatase function.

Group 2: Claim 1, as specifically drawn to a method of screening for biologically active agents comprising combining a candidate biologically active agent with a cell comprising a specific nucleic acid and determining the effect of said agent on phosphatase function.

Group 3: Claim 1, as specifically drawn to a method of screening for biologically active agents comprising combining a candidate biologically active agent with a non-human transgenic animal model comprising a knockout of a specific gene and determining the effect of said agent on phosphatase function.

Group 4: Claim 1, as specifically drawn to a method of screening for biologically active agents comprising combining a candidate biologically active agent with a non-human transgenic animal model comprising an exogenous and stably transmitted mammalian gene sequence and determining the effect of said agent on phosphatase function.

Group 5: Claim 2, drawn to a method for diagnosis of cancer comprising determining the upregulation of expression in a specific polynucleotide.

Group 6: Claim 7, drawn to a method of inhibiting growth of a cancer cell comprising downregulating a specific polypeptide.

Group 7: Claims 12 and 15, as specifically drawn to a method of screening for targets of a cancer associated phosphatase, the method comprising comparing the pattern of

gene expression in a normal cell and in a tumor cell characterized by upregulation of a particular gene.

Group 8: Claims 12 and 15, as specifically drawn to a method of screening for targets of a cancer associated phosphatase, the method comprising comparing the pattern of protein phosphorylation in a normal cell and in a tumor cell characterized by upregulation of a particular gene.

Group 9: Claim 16, drawn to an isolated nucleic acid.

Group 10: Claim 17, drawn to a method to treat a tumor comprising administering a compound of the general formula $\alpha(P_2)$.

Group 11: Claim 28, drawn to a compound for the treatment of a tumor of the general formula $\alpha(P_2)$.

Group 12: Claim 43, drawn to a method for visualizing a tumor in a patient comprising administering a compound of the general formula $\alpha(P_2)$ and visualizing the imaging moieties in the compound.

The Applicant hereby elects to prosecute the claims of Group 1, Claim 1, as specifically drawn to a method of screening for biologically active agents comprising combining a candidate biologically active agent with a specific polypeptide and determining the effect of said agent on phosphatase function, with traverse. As stated in the MPEP §803, if search and examination of an entire application can be made without serious burden, the examiner must examine the entire application on the merits, even though the entire application includes claims to independent or distinct inventions. It is the Applicant's position that it would not be unduly burdensome to perform a search on all of the claims together in the present application. Accordingly, the Applicant traverses the restriction requirement.

Specifically Applicant requests rejoinder of Groups I and II, as the method of screening with a cell comprising the polypeptide, through expression of the polynucleotide encoding the polypeptide, and screening with a polypeptide have an overlapping scope.

Applicant elects the phosphatase MKPX for examination, which corresponds to SEQ ID NO:1 (polynucleotide) and SEQ ID NO:2 (polypeptide).

The Applicant expressly reserves the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.


The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number KINE-040.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: February 7, 2007

By: _____



Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231